The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 ...

Lung cancer stigma stems from its association with smoking, affecting patients' emotional well-being and support systems.

“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Cancer survivorship heightens awareness of synthetic ingredients in everyday products, prompting scrutiny of items like ...

Dr. Ariel Ostad sat down with CURE to discuss the often-overlooked emotional and practical challenges that patients face ...

For patients with blood cancer, it is crucial to own their own cancer journey, as a five-time cancer survivor and author ...

Oya Gilbert, a 55-year-old who was diagnosed with multiple myeloma in 2017, encourages newly diagnosed patients, especially ...

Tukysa, combined with Herceptin and Perjeta, extends progression-free survival in HER2+ metastatic breast cancer, showing ...

Joe McDonough sat down for an interview with CURE to share his family’s story and the inspiration behind the B+ Foundation.